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Abstract
Purpose Functional constipation in children and adolescents
is a common and invalidating condition. In a minority of pa-
tients, symptoms persist despite optimal conservative therapy.
The aim of this study was to evaluate whether the short-term
effects of sacral neuromodulation (SNM) in children and ad-
olescents with constipation are sustained over prolonged pe-
riod of time.
Methods Patients aged 10–20 years, with refractory constipa-
tion, fulfilling the Rome III criteria, were included in our
study. If SNM test treatment showed >50 % improvement in
defecation frequency, a permanent stimulator was implanted.
Primary outcome measure was defecation frequency during
3 weeks. Secondary endpoints were abdominal pain and
Wexner score. To assess sustainability of treatment effect, a
survival analysis was performed. Cross-sectional quality of
life was assessed using the EQ-5D VAS score.
Results Thirty girls, mean age 16 (range 10–20), were includ-
ed. The mean defecation frequency increased from 5.9 (SD
6.5) in 21 days at baseline to 17.4 (SD 11.6) after 3 weeks of
test treatment (p < 0.001). During test treatment, abdominal
pain and Wexner score decreased from 3.6 to 1.5 and 18.6 to
8.5 (p < 0.001), respectively. Improvement of symptoms
sustained during a median follow-up of 22.1 months (12.2–
36.8) in 42.9 % of patients. On a scale from 0 to 100, quality
of life was 7 points lower than the norm score (mean 70 vs. 77).
Conclusion SNM is a therapeutic option for children with
chronic constipation not responding to intensive oral and/or
laxative therapy, providing benefits that appear to be sustained
over prolonged period of time.
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Introduction
Constipation is a common problem in childhood and adoles-
cence, with a prevalence ranging between 0.7 and 29.6 %
(median 12 %) [1]. Functional constipation, as defined by
the ROME III criteria [2], has significant impact on quality
of life, both for the patient as for his or her family [3].
Various modalities have been developed in the treatment of
functional constipation, including increase of dietary fiber in-
take, osmotic and stimulant laxatives, retrograde bowel irriga-
tion, and behavioral therapy, including biofeedback training
and pelvic floor physiotherapy [1, 4]. In the majority of pa-
tients, constipation can be effectively treated by these conser-
vative treatments [5].
A group of patients exists, however, in whom symptoms
persist for many years. In these patients, abdominal pain, most
likely due to the low defecation frequency, is severely disabled
in their daily activities, such as attending school and partici-
pation in sports and social events. For these refractory pa-
tients, surgical procedures such as antegrade bowel irrigation
by means of aMalone stoma, colectomy, or segmental colonic
resection may be considered [6]. Such treatments can, howev-
er, incur complications such as small bowel obstruction,
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chronic diarrhea, fecal incontinence, and abdominal pain;
moreover, long-term results are highly variable [7].
Sacral neuromodulation (SNM) was initially developed as
a treatment for urinary incontinence and retention in adults
[8]. In these series, a subset of patients who suffered from
urinary and fecal incontinence experienced improvement in
both. In adults, studies of SNM for functional bowel com-
plaints showed a positive effect on idiopathic slow and normal
transit constipation resistant to conservative treatment [9]. Our
preliminary data suggest that SNM may also be beneficial in
young patients aged 10–20 years with refractory constipation
[10]. It is unknown, however, whether relief of symptoms is
sustained. In this study, we report longer term follow-up re-
sults with SNM in children and adolescents with constipation
refractory to intensive conservative treatment.
Patients and methods
A prospective cohort study was conducted in a tertiary referral
hospital to assess the efficacy of SNM in adolescents with
refractory constipation. All patients between 10 and 20 years
of age, who were referred to our center for chronic (>1 year)
constipation refractory to conservative treatment, were eligi-
ble to be included in this study. Informed consent was obtain-
ed from all patients and their parents.
All patients met the criteria for functional constipation, as
defined by the Rome III criteria [2]. Demographic data, dis-
ease history, and prior treatments were collected from all pa-
tients. Severity of symptoms was determined at baseline by
means of a 3-week bowel diary, subjective questionnaires, and
Wexner constipation scores [11]. A bowel diary was filled in
during a period of optimal conservative treatment, consisting
of a combination of different oral and/ or rectal laxatives.
Patients were asked to report the frequency of defecation,
presence of straining, episodes being unable to evacuate, urge,
painful defecation, size of stool, abdominal pain, and absence
from school due to constipation-related complaints.
The Wexner score is a composite score ranging from 0 to
30 based on eight domains including frequency, difficulty to
evacuate, completeness, painfulness, duration (time in lavato-
ry), successfulness, and need for assistance in defecation, as
well as history (duration of symptoms) [11].
Further diagnostic tests included defecography to assess
possible outlet obstruction, anal ultrasound, anorectal manom-
etry to exclude Hirschsprung’s disease, colonic transit time
measurement using radio-opaque markers, and MRI of the
lumbar spine.
Operative details
The operative technique for SNM has been described in detail
elsewhere [12]. Briefly, patients had a tined lead (Medtronic
Interstim model 3889) placed in order to perform a test treat-
ment of sacral neuromodulation. This procedure took place
under general anesthesia with antibiotic prophylaxis and was
performed by an experienced surgeon. An X-ray was used to
determine the location of S3 and to place a needle in the
foramen. Correct position of the needle was confirmed by
Bellow’s contraction. Finally, the electrode was placed in po-
sition and connected to the external stimulator. This was
followed by a 3–5-week test period to assess treatment benefit
and decide on implantation of the permanent stimulator. To
qualify for a permanent device, defecation frequency had to be
restored to a frequency of minimally three times per week.
The permanent implantable stimulator (Medtronic Interstim
model 3058) was implanted under local anesthesia. It was
placed in a subcutaneous gluteal pocket under antibiotic pro-
phylaxis. Initial stimulation settings were identical to those
during the testing phase. These stimulation settings are iden-
tical to those used for adults. Initially, a pulsewidth of 210 μs
and a frequency of 16 Hz were used. In the case of unpleasant
sensations or suboptimal treatment effect, settings could be
changed from 120 to 330 μs and 10 to 21 Hz, respectively.
Assessment and follow-up
Patients were followed up at 1, 3, 6, 12, and 24 months after
implantation of the pacemaker. Prior to each follow-up mo-
ment, a 3-week bowel diary was completed, and questionnaires
andWexner constipation scores were recorded. Additional use
of laxatives, recurrence of symptoms, or technical failure with
or without reoperation was recorded. The primary endpoint
was the frequency of defecation as recorded in the 3-week
bowel diary. Treatment was considered successful when defe-
cation frequency was at least three times per week.
Secondary outcome parameters were change in Wexner
constipation score, presence of abdominal pain, pain at defe-
cation, straining, feeling of urge, incomplete evacuation, gen-
eral comfort, and quality of life. Abdominal pain, pain at def-
ecation, straining, feeling of urge, and incomplete evacuation
were assessed using a 5-point scale, ranging from 0 Bnever,^ 1
Brarely,^ 2 Bsometimes,^ 3 Bmost of the times,^ to 4 Balways.^
Quality of life was assessed bymeans of the EQ-5DVAS [13].
Recurrence of constipation was defined as a defecation fre-
quency less than three times per week or the need for use of
laxatives or bowel lavage to control symptoms.
Statistical analysis
Data are presented as mean (SD) or median (range) for con-
tinuous variables, and count (percentage) for categorical var-
iables. Changes over time in severity of symptoms were tested
for statistical significance using paired t test and Wilcoxon
signed ranks test. A time-to-event analysis was conducted
using Kaplan-Meier survival analysis. Event was defined as
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a remission to a defecation frequency of less than three times
per week, with or without lead or pocket revision. Analyses
were conducted using SPSS. A p value of 0.05 was considered
statistically significant.
Results
Thirty patients with refractory constipation were referred to
our center between February 2009 and December 2011.
Table 1 shows the patient characteristics and the progress of
abdominal pain and defecation frequency over time. All 30
patients underwent a test stimulation of SNM. In three of these
patients, test stimulation was ineffective and the electrode was
removed. All remaining 27 patients had a stimulator im-
planted and were available for follow-up. Median follow-up
was 22.1 months (12.2–36.8).
Baseline characteristics
All patients were female with a mean age of 16 years (range
10–20) at the time of the test stimulation. Mean duration of
complaints was 8.1 years (range 1–18). At the time of presen-
tation in our outpatient clinic, all patients had been treated
extensively with various conservative treatments for at least
1 year, under supervision of a referral center. All patients used
Table 1 Baseline characteristics and follow-up



















1 18 18 m 60 np 4 3 2 1 6 m
2 16 6 2 np np 3 2 2 6 6 43
3 15 9 11 np RAIR+ 4 2 3 3 15 93
4 14 9 10 144 np 4 2 2 1 10 65
5 19 18 20 148 RAIR+ 4 2 2 3 12 68
6 17 17 50 148 RAIR+ 4 1 1 9 32 54
7 17 16 20 92 RAIR+ 4 2 1 1 9 57
8 15 14 50 50 RAIR+ 4 1 3 2 3 m
9 13 1 10 50 RAIR+ 4 2 2 6 17 91
10 10 5 12 80 RAIR+ 3 2 0 8 9 22
11 14 4 m np RAIR+ 3 3 x 3 0 x
12 19 10 2 96 RAIR+ 4 0 2 6 54 91
13 14 14 6 np RAIR+ 4 1 m 21 8 69
14 18 16 3 62 RAIR+ 4 2 2 1 21 71
15 17 5 3 38 RAIR+ 3 1 1 9 20 75
16 14 6 3 np np 3 1 1 9 19 70
17 13 13 30 144 RAIR+ 4 3 m 3 15 m
18 18 2 12 np RAIR+ 4 1 2 20 27 60
19 16 2 1 48 RAIR+ 4 0 1 1 24 m
20 15 3 7 136 RAIR+ 2 0 1 8 10 71
21 16 3 4 132 RAIR+ 3 0 m 3 20 80
22 16 1 7 67 RAIR - 3 2 x 1 1 x
23 16 3 9 96 RAIR+ 4 4 m 21 20 m
24 16 10 3 74 RAIR+ 4 4 1 0 4 91
25 16 1 6 86 np 4 1 m 0 15 79
26 16 8 2 120 RAIR+ 3 0 0 0 39 89
27 15 15 25 19 RAIR+ 4 0 m 3 27 59
28 15 8 15 139 RAIR+ 3 3 x 0 0 x
29 15 1 3 np np 4 3 m 0 9 m
30 16 2 2 np np 2 1 2 2 8 m
Abdominal pain: 4 always, 3 most of the tome, 2 sometimes, 1 rarely, 0 never
np not performed; m missing; x electrode removed, no follow-up data available; Def bl defecation frequency at baseline; Def test defecation frequency
during test phase; RAIR recto-anal inhibition reflex: + intact, − no RAIR
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laxatives, including polyethylene glycol, Metamucil,
lactulose, bisacodyl, and magnesium oxide, or a combination
of these, with or without retrograde bowel irrigation. Duration
of laxative use ranged from 1 to 17 years (mean 5.9 years).
One patient had a Malone stoma for antegrade bowel irriga-
tion. All patients had been admitted multiple times to hospital
for either oral and/or rectal lavage (median 7, range 2–50).
Colonic transit time was assessed in 22 of 30 patients and
showed a mean colonic transit time of 92.3 h. Fifteen patients
had colonic transit times exceeding 62 h (Table 1). Lumbar
spineMRI was performed in 22 of 30 patients and revealed no
spinal abnormalities. In 23 of 30 patients, an anorectal ma-
nometry was performed, which showed an abnormal result in
one patient, in whom the anorectal inhibition reflex could not
be elicited (Table 1). In the latter patient, a rectal suction bi-
opsy was performed which showed normal ganglion cells.
Results of defecographywere available for 21 patients. In five,
there was a minimal sign of rectocele (grade 1, smaller than
4 cm), and one patient showed a rectocele, enterocele, and
intussusception. Six patients had no evacuation of the contrast
at all, and in eight patients, evacuation was incomplete.
Twelve patients underwent anal ultrasound. Two of them
showed a defect of approximately 30–45° in the internal and
the external sphincter, respectively. For one, the defect was
possibly the result of sexual abuse. In the remaining 10 pa-
tients, no abnormalities were found on anal ultrasound.
Defecation frequency
At baseline, the mean defecation frequency during a 3-week
period was 5.9 (SD 6.5) or 1.96 times per week. During the
test phase, the mean defecation frequency increased to 17.4
(SD 11.6) per 3 weeks or 5.8 times per week. During follow-
up, the mean defecation frequency remained stable at this
level. At each time at follow-up, the defecation frequency
was significantly higher when compared to baseline defeca-
tion frequency (p < 0.001).
Secondary outcome parameters
The mean Wexner score decreased from 18.6 (SD 8.5) at
baseline to 8.2 (SD 8.3) during test phase and remained stable
during follow-up (Fig. 1). At each follow-up visit, the mean
Wexner score was significantly lower as compared to baseline
(p < 0.001). The abdominal pain score decreased from mean
3.62 at baseline to 1.53 at 1 year follow-up (p < 0.001). At
baseline, two patients reported to have abdominal pain some
of the time, while the other patients reported to have abdom-
inal pain most of the time (9) or always (19). At 1 year follow-
up, two patients still had abdominal painmost of the time, nine
sometimes, seven rarely, and two never. Accompanying
symptoms such as pain at defecation, straining, and incom-
plete evacuation showed a comparable decrease, while the
times of feeling of urge increased. The EQ5D VAS score
was 69.90 (SD 17.96) at a median follow-up of 12 months,
which is lower than the norm score for healthy Dutch females
aged 15–19 (mean 76.73, SD 12.58) (Table 1) [13].
Complications and revisions
A total number of 15 revisions were performed in 12 patients.
Reasons for revision were the following: recurrence of symp-
toms in six patients, a lead revision was performed; pain at the
site of the stimulator in five patients, the position of the stim-
ulator was revised; and infection of the electrode in one pa-
tient, the electrode was removed and a new test was performed
after 4 weeks. No other, more serious adverse events associ-
ated with the surgical procedure were observed. At the end of
follow-up, 21 of 27 patients were still on SNM therapy.
Fifteen of 27 patients failed on SNM, six of these patients
underwent a total colectomy and subsequently had the stimu-
lator removed. The remaining nine patients combined SNM
with laxatives and/or bowel irrigation.
Survival analysis
Figure 2 shows the results of the time-to-event analysis, where
an event is defined as a decrease of defecation frequency be-
low three times per week, with or without revision. The figure
shows that in this population of patients with chronic consti-
pation, refractory to conservative treatment, the 2-year recur-
rence-free survival was approximately 42.9 %. These events
mainly occurred in the first year after treatment, as after 6 and
12 months, the recurrence-free survival was 58 and 50 %,
respectively.
Discussion
This study shows that in some patients, SNM has a long-
lasting beneficial effect on defecation frequency and accom-
panying symptoms such as abdominal pain and difficulties
with evacuation in adolescent patients with severe constipa-
tion resistant to conservative treatment.
Sacral nerve modulation in our cohort of children and
adolescents with therapy-resistant constipation shows
similar efficacy and safety rates as in adults with refrac-
tory constipation [9]. Improvement in defecation-related
parameters has been reported in adults, in terms of defe-
cation frequency, abdominal pain, and use of laxatives.
Many different outcome parameters are used however,
which makes adequate comparison difficult, and this
probably also results in the wide range of success rates
(42–100 %) [14, 15]. In the prospective study by Kamm
et al., the indication to proceed to permanent implantation
was an improvement of at least 50 % in defecation
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frequency or a frequency of three or more per week as
well. This resulted in a success rate of 63 % at a median
follow-up of 28 months [9]. The higher success rates re-
ported of SNM for constipation in adults compared to the
current population is possibly a result from the severity of
symptoms these adolescents experience. Moreover, this
finding contributes to the suggestion of different etiolo-
gies of constipation for children and adults [1].
A recent study in children with fecal and urinary inconti-
nence and constipation reported that six of 11 patients with a
pre-SNM cecostomy tube no longer required an antegrade
bowel regimen as they had voluntary bowel movements
[16]. Furthermore, ten of 11 patients (91%) no longer required
anticholinergic medications for bladder overactivity after re-
ceiving SNM. Since the short-term follow-up in this small









Fig. 1 Box plot ofWexner scores
at baseline (b), during test phase
(t), and at 1, 3, 6, 12, and
24 months follow-up,
respectively. n = 30/30 (baseline),
n = 30/30 (test), n = 27/27 (1),
n = 24/27 (3), n = 25/27 (6),
n = 20/27 (12), and n = 10/25
























Fig. 2 Kaplan-Meier survival
curve, showing recurrence of
constipation symptoms over time.
Censored observations represent
end of follow-up. End-point is
recurrence of symptoms, with or
without reoperation. x-axis: days
to event. y-axis: cumulative
survival
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are required to identify longer-term effects of SNM for pa-
tients with bowel and bladder dysfunction and potentially
identify subgroups of patients that are more likely to respond
to sacral neuromodulation. Our study shows that the 2-year
recurrence-free survival was approximately 42.9 %, without
major complications. Based on these results, we decided not
to remove the permanent stimulator in these successfully treat-
ed patients. Data are lacking to estimate after which time it is
possible to switch off and remove the stimulator [9, 16].
Of the 21 patients who underwent defecography, only 1 did
not show some degree of evacuatory dysfunction. Knowles
et al. suggested that evacuatory dysfunction should not be an
exclusion criterion for SNM [17]. It might even lead to sen-
sory improvement in patients suffering from rectal
hyposensitivity. Unfortunately, follow-up data of manometry
to assess dyssynergia and rectal sensitivity are not available
for the cohort of patients in this trial.
In 15 out of 22 patients in whom colonic transit time was
assessed at baseline, colonic transit appeared to be delayed.
The increase in defecation frequency suggests that colonic
transit time improves after SNM. Clarke et al. concluded that
colonic transit time was significantly shorter after interferen-
tial therapy (IFT) compared to sham [18]. IFT, a form of trans-
cutaneous electrical nerve stimulation (TENS) [19, 20], is
similar to SNM as both techniques aim to modulate neural
activity by electrical stimulation. However, IFT is even less
invasive as it makes use of surface electrodes and transcuta-
neous stimulation instead of the percutaneous implantation of
an electrode, which is connected to an implantable stimulator.
Indeed, children with slow transit constipation, who failed
conventional therapy, were effectively treated with TENS
[19, 20]. More importantly, after daily treatment for 1–
6 months, colonic function improved for several years and
some children were even able to withdraw medication.
Large randomized controlled trials are required to compare
both neuromodulation techniques in both children and adults
with refractory constipation.
The extensive diagnostic workup prior to the test period
was performed in an attempt to identify possible prognostic
factors for success regarding SNM. Unfortunately, the number
of patients in this study is too small to draw any conclusions in
this regard.
The high rate of revisions in this population is the major
drawback of this surgical intervention. In accordance with the
other pediatric study, in approximately half of the cases, the
indication for revision was pain in the area of the implanted
stimulator [16]. This is despite the fact that we already im-
planted the smallest device (Medtronic Interstim2, model
3889). The other revisions were because of recurrence of
symptoms. Important to note is that the present population is
very young and active, which may partially explain the higher
lead revision rate when compared to adults [21]. Another fac-
tor that may be of influence is the fact that these young
patients are still growing, affecting lead position [22]. The
majority of relapses that could not be resolved by revision
occurred during the first year after implantation. Possible ex-
planations for such relapses include gradual adjustment of the
pelvic floor and colon to the new stimulation or weaning of an
initial placebo effect or other psychological phenomenon.
For fecal incontinence, SNM appeared to be cost-effective
[10, 23]. For constipation, these analyses have not been per-
formed yet. The high costs associatedwith the techniquemake
funding more problematic, which probably contributes to the
fact that this treatment is not commonly used. The direct costs
from the electrode and the stimulator are approximately 8000
euros [24]. Childhood constipation is a common problem and
brings a great economic burden to the public health system
[25]. The study by Liem et al. reported that in the USA, the
yearly costs of children with constipation were three times
higher than those of children without constipation [26]. So,
adequate treatment of this condition potentially leads to a ma-
jor reduction in costs due to frequent admissions. For a treat-
ment to be cost-effective, the effect on symptoms and quality
of life needs to be taken into account. Unfortunately, from the
patients in this study, no data on quality of life before treat-
ment are available. However, in general, the quality of life
seems to be impaired in children with constipation [27].
Therefore, it is promising to see that after SNM, quality of life
was only 6 points lower than in the general population (on a
scale from 0 to 100), especially considering the fact that this
group at baseline suffered from the worst complaints in the
spectrum.
A major limitation of our study is its observational, non-
comparative nature. Causally attributing the improvement in
symptoms that we observed to the SNM therefore critically
hinges on the assumption that, in the absence of treatment, no
such recovery would have occurred. In a survey conducted
among residents of Olmsted County, MN, aged 30–64 years,
Talley et al. (1992) studied the onset and disappearance of
symptoms consistent with functional gastrointestinal disor-
ders, including constipation. They found that 89 % of the
population surveyed had no change in their symptoms during
a period of 12–20months, suggesting a relative stability in this
patient population [28]. Similarly, we cannot exclude the pos-
sibility that at least part of the observed improvement may
result from a nonspecific placebo effect [29]. To explore these
issues further, a randomized, double-blind trial is currently
prepared in our center, comparing SNM with sham SNM in
children and adolescents with chronic constipation refractory
to conservative treatment. A debate among healthcare profes-
sionals, patients, and commissioning organizations on the
question whether such a study would be appropriate and eth-
ically acceptable is necessary. In such a study, attention should
be addressed to the fact that studies on SNM with an obser-
vational design encounter the problem that patients who do
not benefit from the treatment and proceed to other treatments
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are lost to follow-up and therefore in the long-term selection
takes place. A recently performed review of the literature
clearly stated that although SNM appears to be an effective
treatment for constipation, larger studies with longer follow-
up are needed [15]. An important issue would be to explain
heterogeneity in treatment response, allowing for better
counseling of patients or patient selection. Clearly, this would
require numbers of patients usually not enrolled in single-
center studies. To allow for pooled analysis of data from mul-
tiple studies in the future, standardization in definitions, as-
sessments, and reporting is vitally important.
In conclusion, for this group of adolescent patients with
severe complaints of constipation resistant to conservative
treatment, SNM is an effective treatment with beneficial effect
on defecation frequency and abdominal pain.
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